

Antibiotic	Year	COMMUNITY			HOSPITAL			TOTAL		
		Number of community isolates tested	R n (%)	95% CI of resistance percentage	Number of hospital isolates tested	R n (%)	95% CI of resistance percentage	Total number of isolates tested*	R n (%)	95% CI of resistance percentage
Ampicillin	2009	835	331 (39.6)	36.3–43.1	143	71 (49.7)	41.2–58.1	978	402 (41.1)	38.0–44.3
	2010	897	358 (39.9)	36.7–43.2	182	70 (38.5)	31.4–45.9	1079	428 (39.7)	36.7–42.7
	2011	1037	443 (42.7)	39.7–45.8	189	91 (48.2)	40.8–55.5	1226	534 (43.6)	40.8–46.4
	2012	939	412 (43.9)	40.7–47.1	173	74 (42.8)	35.3–50.5	1112	486 (43.7)	40.8–46.7
	2013	784	315 (40.2)	36.7–43.7	154	71 (46.1)	38.1–54.3	938	386 (41.2)	38.0–44.4
	Total	4492	1859 (41.4)	39.9–42.8	841	377 (44.8)	41.4–48.3	5333	2236 (41.9)	40.6–43.3
AMC	2009	785	24 (3.1)	2.0–4.5	133	6 (4.5)	1.7–9.6	918	30 (3.3)	2.2–4.6
	2010	832	49 (5.9)	4.4–7.7	172	11 (6.4)	3.2–11.2	1004	60 (6.0)	4.6–7.6
	2011	981	61 (6.2)	4.8–7.9	170	17 (10.0)	5.9–15.5	1151	78 (6.8)	5.4–8.4
	2012	895	71 (7.9)	6.2–9.8	161	19 (11.8)	7.3–17.8	1055	89 (8.4)	6.8–10.3
	2013	754	58 (7.7)	5.9–9.8	145	23 (15.9)	10.3–22.8	899	81 (9.0)	7.2–11.1
	Total	4247	263 (6.2)	5.5–6.9	781	76 (9.3)	7.7–12.0	5027	338 (6.7)	6.0–7.5
Cefazolin	2009	821	60 (7.3)	5.6–9.3	129	14 (10.9)	6.1–17.5	950	74 (7.8)	6.2–9.7
	2010	885	96 (10.9)	8.9–13.1	179	24 (13.4)	8.8–19.3	1064	120 (11.3)	9.4–13.3
	2011	1019	103 (10.1)	8.3–12.1	178	30 (16.9)	11.7–23.2	1197	133 (11.1)	9.4–13.0
	2012	917	82 (8.9)	7.2–11.0	168	26 (15.5)	10.4–21.8	1085	108 (10.0)	8.2–11.9
	2013	776	89 (11.5)	9.3–13.9	151	30 (19.9)	13.8–27.1	927	119 (12.8)	10.8–15.2
	Total	4418	430 (9.7)	8.9–10.6	805	124 (15.4)	13.0–18.1	5223	554 (10.6)	9.8–11.5
Trimethoprim	2009	830	153 (18.4)	15.9–21.2	143	28 (19.6)	13.4–27.0	973	181 (18.6)	16.2–21.2
	2010	897	172 (19.2)	16.6–21.9	181	33 (18.2)	12.9–24.6	1078	205 (19.0)	16.7–21.5
	2011	1036	217 (20.9)	18.5–23.6	189	42 (22.2)	16.5–28.8	1225	259 (21.1)	18.9–23.5
	2012	939	200 (21.3)	18.7–24.1	173	40 (23.1)	17.1–30.1	1112	240 (21.6)	19.2–24.1
	2013	784	181 (23.1)	20.2–26.2	154	36 (23.4)	16.9–30.9	938	217 (23.1)	20.5–26.0
	Total	4486	923 (20.6)	19.4–21.8	840	179 (21.3)	18.6–24.2	5326	1102 (20.7)	19.6–21.8
Nalidixic acid	2009	826	63 (7.6)	5.9–9.7	143	12 (8.4)	4.4–14.2	969	75 (7.7)	6.1–9.6
	2010	892	73 (8.2)	6.5–10.2	182	12 (6.6)	3.5–11.2	1074	85 (7.9)	6.4–9.7
	2011	1034	109 (10.5)	8.7–12.6	188	22 (11.7)	7.5–17.2	1222	131 (10.7)	9.0–12.6
	2012	755	56 (7.4)	5.7–9.5	140	17 (12.1)	7.2–18.7	895	73 (8.2)	6.4–10.1
	2013	585	33 (5.6)	3.9–7.8	103	11 (10.7)	5.5–18.3	688	44 (6.4)	4.7–8.5
	Total	4092	334 (8.2)	7.3–9.0	756	74 (9.8)	7.8–12.1	4848	408 (8.4)	7.6–9.2
Ciprofloxacin	2009	808	33 (4.1)	2.8–5.7	139	7 (5.0)	2.0–10.1	947	40 (4.2)	3.0–5.7
	2010	701	35 (5.0)	3.5–6.9	150	4 (2.7)	0.7–6.7	851	39 (4.6)	3.3–6.2
	2011	795	52 (6.5)	4.9–8.5	156	10 (6.4)	3.1–11.5	951	62 (6.5)	5.0–8.3
	2012	749	56 (7.5)	5.7–9.6	143	11 (7.7)	3.9–13.3	892	67 (7.5)	5.9–9.4
	2013	631	60 (9.5)	7.3–12.1	135	17 (12.6)	7.5–19.4	766	77 (10.1)	8.0–12.4
	Total	3684	236 (6.4)	5.6–7.2	723	49 (6.8)	5.1–8.9	4407	285 (6.5)	5.8–7.2
Gentamicin	2009	514	17 (3.3)	1.9–5.2	85	5 (5.9)	1.9–13.2	599	22 (3.7)	2.3–5.5
	2010	893	23 (2.6)	1.6–3.8	182	2 (1.1)	0.1–3.9	1075	25 (2.3)	1.5–3.4
	2011	1036	38 (3.7)	2.6–5.0	189	12 (6.4)	3.3–10.8	1225	50 (4.1)	3.0–5.3
	2012	931	40 (4.3)	3.1–5.8	172	12 (7.0)	3.7–11.9	1102	52 (4.7)	3.5–6.1
	2013	783	36 (4.6)	3.2–6.3	154	10 (6.5)	3.2–11.6	937	46 (4.9)	3.6–6.5
	Total	4157	154 (3.7)	3.2–4.3	782	41 (5.2)	3.8–7.0	4938	195 (3.9)	3.4–4.5

\*Note that not all 5333 isolates were tested against each antimicrobial. Isolates not tested: AMC = 3; Cephazolin = 110; Trimethoprim = 3; Nalidixic acid = 485; Ciprofloxacin = 893; Gentamicin = 395

Number of isolates with intermediate susceptibility to an antimicrobial: AMC = 303; Trimethoprim = 4; Ciprofloxacin = 33

R = Resistant

n = Number of isolates

AMC = Amoxicillin-clavulanate; TMP-SMX = Trimethoprim-sulphamethoxazole